Search

Phage Consultants CEO Marcin Łoś was at PHI Korea in Seoul for the first time, meeting Asian clients and potential partners and presenting the company’s portfolio, including swab sampling and virulent phage testing. Phage Consultants

This Zenodo archive contains PHORAGER outputs from a prophage-mining analysis of publicly available ESKAPE pathogen genomes, packaged as one ZIP file per species. PHORAGER ESKAPE prophage output dataset

MicrobiotiX reported completion of the sentinel cohort in its Phase 1 MP101 trial for Pseudomonas aeruginosa pneumonia. The initial 72-hour assessment raised no safety concern that prevented continuation, and Cohort 1 enrollment was proceed

Pauliina Lajunen joined PrecisionPhage as Chief Business Officer in August 2026. PrecisionPhage

An atlas maps 8,484 interactions between 84 phages and 101 clinical Klebsiella strains, alongside GenoPHI. A Nature Microbiology study describes the genome-only model across 115,037 interactions, with experimental validation of 1,240 E. col

EMBL Heidelberg researchers report in Nature that the kinase of phage T7 (T7K) causes almost every bacterial protein to be phosphorylated, at least in part of its pool, within minutes of infection, preferentially targeting DNA-binding prote

Armata said it was finalizing activities for a pivotal Phase 3 superiority study of AP-SA02 in complicated Staphylococcus aureus bacteremia, anticipated to start in the second half of 2026. Armata Pharmaceuticals

A peer-reviewed expanded-access case report in Clinical Infectious Diseases describes investigational SNIPR001 use in a kidney transplant recipient with progressive multidrug-resistant Escherichia coli malakoplakia, under a single-patient e

On 12 August 2026 the LEO Foundation announced DKK 61.9 million in Research Grants to 16 international projects, including one to Professor Thomas Sicheritz-Pontén (University of Copenhagen); the foundation's grantee record lists his 2026 R

Stanford researchers led by Brian Hie and Samuel King used Evo 2, a generative AI model that writes whole genomes, to design novel bacteriophage genomes starting from ΦX174. They synthesized nearly 300 phages, tested them against E. coli an

Four CEPID B3 researchers represented the center at Viruses of Microbes in Prague, presenting work on Salmonella phage diversity and approaches to expand phage host range against Escherichia coli. CEPID B3

The M. Iashvili Children’s Central Hospital, Georgia’s only tertiary, multidisciplinary pediatric referral hospital, and the George Eliava Institute of Bacteriophages, Microbiology and Virology have signed a memorandum of cooperation. The h

Hebrew University and Hadassah Medical Center are partners in P-PEAKS UTI, a €15 million international project evaluating personalized phage therapy for recurrent E. coli urinary tract infections. The study plans to enrol approximately 220

Uruguayan biotechnology company Kinzbio reports the first application of phage therapy at Uruguay's Banco de Prótesis, treating a 30-year-old patient with a hip prosthesis infection caused by an antibiotic-resistant Stenotrophomonas maltoph

The First Affiliated Hospital of Xi’an Jiaotong University and CreatiPhage signed an agreement on July 8, 2026, to build a phage bank and establish a research project. CreatiPhage

Nicholas Smith will lead nuclear imaging and phage pharmacokinetics research and the pharmacology and modelling core at Stanford’s $9.5 million Center for Phage Pharmaceuticals. The NIAID-funded work focuses on optimizing respiratory phage

A model infers differences between individual phage infections from population-level measurements, checked against single-cell experiments in a marine phage–cyanobacterium system. University of Maryland — Jennifer Holland

A McMaster team developed a targeted phage approach to disarm adherent-invasive E. coli linked to inflammation in some people with Crohn’s disease. In controlled experimental models, phages reduced gut inflammation by changing bacterial beh

Dr. Gregory German of Unity Health Toronto will lead P-PEAKS UTI, an international clinical trial in which about 220 women with E. coli urinary tract infections lasting a year or more will receive either personalized phage therapy or placeb

Judith Sar discusses the regulation of E. coli F anti-phage defense genes during T5 infection in a Phages.fr talk hosted on Canal-U. Phages.fr on Canal-U